Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels. - Wikidata - awgldk - TriplyDB

Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels.

Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels.

http://www.wikidata.org/entity/Q37356074

about

Human pluripotent stem cell models of Fragile X syndrome.Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (FMR1) Gene Reactivation in Human Neural Cells.Inhibitors of Histone Deacetylases Are Weak Activators of the FMR1 Gene in Fragile X Syndrome Cell Lines.

P2860

Q38660520-F5A19DA5-7A1A-4FF5-93E2-B2D6B0682E76 Q39597255-389C45F9-B7A4-4C48-866B-0F09545022CE Q47325351-1FDC0FB6-8E17-48F0-A98E-A2F8513CD178

P2860

Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels.

http://www.wikidata.org/entity/Q37356074

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@en

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@nl

type

label

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@en

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@nl

prefLabel

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@en

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@nl

P1433

Q37356074-9B2D7A30-FEDC-4040-AFE2-5CF5F81A671A

P1476

Q37356074-1FD3D5FE-12B4-4EE3-8A9F-121ECD2CD7EE

P2093

Q37356074-06355D15-657D-40BC-9A8C-47D0FF79CA00

Q37356074-C516F682-4D83-493F-B345-6376D8866A1B

Q37356074-D943F45C-58C0-4C59-8F86-8C237F03DE11

Q37356074-E91FE5DE-2527-41CE-A25A-6ED29659EFD7

Q37356074-EA137F2C-5D0E-4A11-A567-E9D5C07CDB73

P2860

Q37356074-06D93BB7-4CB0-4F2E-9A87-F186D9EC7F88

Q37356074-1290B3C9-DE50-4222-A474-0A10C55E2FE2

Q37356074-16354FCA-0A6C-433A-9815-F27EA03BC3D3

Q37356074-16DA993A-F4AE-471B-8CEA-2D9F7AF027B3

Q37356074-1A15383A-FACB-44C5-8C9D-D01F0B9FF086

Q37356074-1C847393-B577-4564-B91D-28572D25D77C

Q37356074-2B122DA0-2320-429E-AAD9-779EAE6E4B9C

Q37356074-2DA72E62-4FC7-4300-B4EF-80287E4BB643

Q37356074-32EB466C-FEA9-42D2-B999-154C773AF14B

Q37356074-398C7462-33A6-4F75-B629-C33F56F6F378

P2888

Q37356074-21C6D16D-E685-4D95-810D-3A35630CB78E

P304

Q37356074-0EAC63AB-00F1-425C-903D-FD8092DB1431

P31

Q37356074-1B370B32-C4D5-42AB-92E9-698F26AF00EA

P356

Q37356074-8D0A577E-36C8-467E-A3B6-7E5017A604C3

P433

Q37356074-678BD9DD-47B2-4B27-9A01-32FA6CDD5EA3

P478

Q37356074-166182E6-AEE7-4FFC-BD2D-71302F1BAD54

P577

Q37356074-E9D3A7E4-9F04-475A-B653-7E1AE09AEEED

P5875

Q37356074-140D7B49-C120-4F01-AE4E-511C23DD50EA

P6179

Q37356074-75251E6A-362B-49A7-B040-84CF459E387A

P698

Q37356074-4FF350DF-EB0B-49CA-8B31-E23AE6A2ED82

P932

Q37356074-1F9C334C-BE62-49C6-A45E-63E6C28A26D8

P356

P1433

Journal of Neurodevelopmental Disorders

P1476

Methotrexate treatment of FraX ...... etectable FMR1 protein levels.

@en

P2093

Benjamin Mielke

http://www.w3.org/2001/XMLSchema#string

Cornelia Brendel

http://www.w3.org/2001/XMLSchema#string

Jutta Gärtner

http://www.w3.org/2001/XMLSchema#string

Merle Hillebrand

http://www.w3.org/2001/XMLSchema#string

Peter Huppke

http://www.w3.org/2001/XMLSchema#string

P2860

FMR1 protein: conserved RNP family domains and selective RNA binding

Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

The mGluR theory of fragile X mental retardation

De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines.

Genome-wide analysis validates aberrant methylation in fragile X syndrome is specific to the FMR1 locus.

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.

Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome.

Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation.

P2888

P304

23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1866-1955-5-23

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256488833

http://www.w3.org/2001/XMLSchema#string

P6179

1027243474

http://www.w3.org/2001/XMLSchema#string

P698

24020679

http://www.w3.org/2001/XMLSchema#string

P932

3846751

http://www.w3.org/2001/XMLSchema#string